Previous close | 1,954.25 |
Open | 1,954.25 |
Bid | 1,902.00 x 0 |
Ask | 1,934.00 x 0 |
Day's range | 1,954.25 - 1,954.25 |
52-week range | 1,918.00 - 2,798.00 |
Volume | |
Avg. volume | 78 |
Market cap | 125.557B |
Beta (5Y monthly) | 0.81 |
PE ratio (TTM) | 23.53 |
EPS (TTM) | 83.06 |
Earnings date | 01 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Company Announcement COPENHAGEN, Denmark; June 10, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from June 3, 2024, to June 7, 2024: Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announceme
Media Release COPENHAGEN, Denmark; June 05, 2024Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Operating Officer Anthony Mancini will participate in a fireside chat at the Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, Florida 9:20 AM EDT (3:20 PM CEST) on June 10, 2024. A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content. About Genmab Genmab is
COPENHAGEN, Denmark, June 03, 2024--Genmab A/S (Nasdaq: GMAB) announced today that data from the Phase 2 innovaTV 207 trial (NCT03485209) Part C (n=40), investigating tisotumab vedotin, an antibody-drug conjugate directed to tissue factor, demonstrated encouraging antitumor activity as a monotherapy in patients with head and neck squamous cell carcinoma (HNSCC) who experienced disease progression on or after first-line therapy. The study showed 32.5% of patients achieved a confirmed objective re